![Johan Järte](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Johan Järte
Profile
Johan Järte was the Chief Executive Officer at SentoClone AB.
Former positions of Johan Järte
Companies | Position | End |
---|---|---|
SentoClone AB
![]() SentoClone AB Miscellaneous Commercial ServicesCommercial Services SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn. | President | 31/12/2012 |
Experiences
Positions held
Linked companies
Private companies | 1 |
---|---|
SentoClone AB
![]() SentoClone AB Miscellaneous Commercial ServicesCommercial Services SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn. | Commercial Services |
- Stock Market
- Insiders
- Johan Järte